Literature DB >> 27275374

Detection of Synchronous Parathyroid Adenoma and Breast Cancer with (18)F-Fluorocholine PET-CT.

Wessel McM Vorselaars1, Wouter P Kluijfhout1, Menno R Vriens1, Carmen C van der Pol1, Inne Hm Borel Rinkes1, Gerlof D Valk2, Bart de Keizer3.   

Abstract

Entities:  

Year:  2015        PMID: 27275374      PMCID: PMC4870458          DOI: 10.1007/s13139-015-0357-x

Source DB:  PubMed          Journal:  Nucl Med Mol Imaging        ISSN: 1869-3474


× No keyword cloud information.
A 71-year-old woman was referred to our tertiary care center for evaluation of asymptomatic recurrence of primary hyperparathyroidism. As per our protocol, the patient underwent neck/mediastinum 18F-fluorocholine (FCH) positron emission tomography-computed tomography (PET-CT) for localization. In our institution, FCH PET-CT is performed in patients with hyperparathyroidism and negative conventional imaging [1]. FCH PET-CT is a promising new imaging modality for detection of hyperfunctioning parathyroid glands [2, 3]. Thirty minutes after injection of 139 MBq (3.8 mCi), the PET-CT images showed a focal uptake (SUVmax = 1.8) at the lower anterior neck, level VI, anterior to the right common carotid artery (Fig. 1a-f), suspicious for parathyroid adenoma. Additionally, it showed a second focal uptake (SUVmax = 2.5) in a nodal structure measuring 1.2 cm, within the outer lower quadrant of the right breast (Fig. 2a-f). No other pathological uptake was seen. On the subsequent ultrasound (US) of the breast, there was an area of microcalcifications seen with no definite abnormal lesion. US of the axilla was negative for any suspicious lesions. Mammography showed a blurry 1.3-cm mass without clear boarders and microcalcifications within relatively dense fibro-glandular tissue (BI-RADS IV). US-guided core biopsy showed papillary carcinoma. Pathological examination after breast-conserving surgery revealed papillary breast cancer of 1.0 cm, staged pT1N0. The location of the cancer corresponded with that indicated by FCH PET-CT. Due to the finding of breast cancer, surgery for primary hyperparathyroidism was postponed.
Fig. 1

18F-Fluorocholine PET-CT of the neck/mediastinum: axial (a-c) and coronal (d-f) PET, CT and fused PET-CT images showing a focal uptake (SUVmax = 1.8) at the lower anterior neck, level VI, anterior to the right common carotid artery, suggesting parathyroid adenoma

Fig. 2

18F-Fluorocholine PET-CT of the neck/mediastinum: axial (a-c) and coronal (d-f) PET, CT and fused PET-CT images showing an additional focal uptake (SUVmax = 2.5) in a nodal structure of 1.2 cm located in the lateral lower quadrant of the right breast

18F-Fluorocholine PET-CT of the neck/mediastinum: axial (a-c) and coronal (d-f) PET, CT and fused PET-CT images showing a focal uptake (SUVmax = 1.8) at the lower anterior neck, level VI, anterior to the right common carotid artery, suggesting parathyroid adenoma 18F-Fluorocholine PET-CT of the neck/mediastinum: axial (a-c) and coronal (d-f) PET, CT and fused PET-CT images showing an additional focal uptake (SUVmax = 2.5) in a nodal structure of 1.2 cm located in the lateral lower quadrant of the right breast Currently, mammography and US are considered the standard of care in the preoperative workup of breast cancer [4]. Multiple other imaging modalities, including positron emission mammography (PEM) with a variety of radionuclide tracers as well as magnetic resonance imaging (MRI), are currently under investigation [5-7]. Breast cancer has previously been found to have increased uptake of choline [8]. Therefore, the use of 11C-choline PET/CT has been used to accurately localize these malignant tumors [9]. One major drawback is that the half-life of 11C-methionine is only 20 min. This requires on-site production of the tracer to be used in the study, thereby strongly limiting its clinical applicability. The half-life of FCH is 110 min, enabling off-site production and distribution, making it much more practical to use as an imaging modality in this context [10]. Furthermore, FCH is already being used in the evaluation of prostate cancer and is therefore more widely available than other radiotracers [11, 12]. As can be seen in the case presented, high FCH uptake was seen in a small breast cancer. Due to its favorable half-life and wide availability by its use as a localization technique for patients with prostate cancer and complicated hyperparathyroidism, FCH PET-CT may be a new promising modality in the imaging of breast cancer.
  12 in total

1.  ¹⁸F-Fluorocholine PET/CT for localization of hyperfunctioning parathyroid tissue in primary hyperparathyroidism: a pilot study.

Authors:  Luka Lezaic; Sebastijan Rep; Mojca Jensterle Sever; Tomaz Kocjan; Marko Hocevar; Jure Fettich
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-07-26       Impact factor: 9.236

2.  Enabling minimal invasive parathyroidectomy for patients with primary hyperparathyroidism using Tc-99m-sestamibi SPECT-CT, ultrasound and first results of (18)F-fluorocholine PET-CT.

Authors:  Wouter P Kluijfhout; Wessel M C M Vorselaars; Menno R Vriens; Inne H M Borel Rinkes; Gerlof D Valk; Bart de Keizer
Journal:  Eur J Radiol       Date:  2015-05-21       Impact factor: 3.528

3.  Breast cancer: a new imaging approach as an addition to existing guidelines.

Authors:  Monique D Dorrius; Erik F J de Vries; Riemer H J A Slart; Andor W J M Glaudemans
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-03-12       Impact factor: 9.236

4.  Detection of breast cancer with addition of annual screening ultrasound or a single screening MRI to mammography in women with elevated breast cancer risk.

Authors:  Wendie A Berg; Zheng Zhang; Daniel Lehrer; Roberta A Jong; Etta D Pisano; Richard G Barr; Marcela Böhm-Vélez; Mary C Mahoney; W Phil Evans; Linda H Larsen; Marilyn J Morton; Ellen B Mendelson; Dione M Farria; Jean B Cormack; Helga S Marques; Amanda Adams; Nolin M Yeh; Glenna Gabrielli
Journal:  JAMA       Date:  2012-04-04       Impact factor: 56.272

5.  Role of 18F-choline PET/CT in biochemically relapsed prostate cancer after radical prostatectomy: correlation with trigger PSA, PSA velocity, PSA doubling time, and metastatic distribution.

Authors:  Maria Cristina Marzola; Sotirios Chondrogiannis; Alice Ferretti; Gaia Grassetto; Lucia Rampin; Arianna Massaro; Paolo Castellucci; Maria Picchio; Adil Al-Nahhas; Patrick M Colletti; Adriano Marcolongo; Domenico Rubello
Journal:  Clin Nucl Med       Date:  2013-01       Impact factor: 7.794

6.  [11C]choline positron emission tomography in estrogen receptor-positive breast cancer.

Authors:  Kaiyumars B Contractor; Laura M Kenny; Justin Stebbing; Adil Al-Nahhas; Carlo Palmieri; Dudley Sinnett; Jacqueline S Lewis; Katy Hogben; Safiye Osman; Sami Shousha; Charles Lowdell; R Charles Coombes; Eric O Aboagye
Journal:  Clin Cancer Res       Date:  2009-08-25       Impact factor: 12.531

7.  Molecular causes of the aberrant choline phospholipid metabolism in breast cancer.

Authors:  Kristine Glunde; Chunfa Jie; Zaver M Bhujwalla
Journal:  Cancer Res       Date:  2004-06-15       Impact factor: 12.701

8.  Is 18F-fluorocholine-positron emission tomography/computerized tomography a new imaging tool for detecting hyperfunctioning parathyroid glands in primary or secondary hyperparathyroidism?

Authors:  Laure Michaud; Alice Burgess; Virginie Huchet; Marine Lefèvre; Marc Tassart; Jessica Ohnona; Khaldoun Kerrou; Sona Balogova; Jean-Noël Talbot; Sophie Périé
Journal:  J Clin Endocrinol Metab       Date:  2014-12       Impact factor: 5.958

9.  Impact of 18F-choline PET/CT in prostate cancer patients with biochemical recurrence: influence of androgen deprivation therapy and correlation with PSA kinetics.

Authors:  Mohsen Beheshti; Silke Haim; Rasoul Zakavi; Martin Steinmair; Peter Waldenberger; Thomas Kunit; Michael Nader; Werner Langsteger; Wolfgang Loidl
Journal:  J Nucl Med       Date:  2013-04-04       Impact factor: 10.057

10.  Diagnostic performance of dedicated positron emission mammography using fluorine-18-fluorodeoxyglucose in women with suspicious breast lesions: a meta-analysis.

Authors:  Carmelo Caldarella; Giorgio Treglia; Alessandro Giordano
Journal:  Clin Breast Cancer       Date:  2013-12-27       Impact factor: 3.225

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.